40 patents currently held
21 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2028. from the record
Of the 21 now held by other companies, 6 name Pgi Drug Discovery LLC as their current owner, and 15 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
9
Ending by 2030
Jan 2028
Next term end
24
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends no later than Dec 2031 · Low confidence
Also notable
Ends May 2031 · High confidence
Also notable
Ends no later than Jun 2030 · Medium confidence
Sublingual Films
US 10,285,953
Cited by 42 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2031. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Substituted Quinoxalines and Quinoxalinones as PDE-10 Inhibitors
US 8,969,349
Cited by 36 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Sublingual Apomorphine
US 9,044,475
Cited by 36 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 23 to 26, 2026 · next Nov 23
- 1 fee due Dec 2, 2026The maintenance fee for Sublingual Apomorphine (US 9,044,475) comes due Dec 2, 2026. Unpaid by Jun 2, 2027, it lapses early.
- 2 fees due Feb 6 to 13, 2027 · next Feb 6
- 2 fees due Mar 24 to 26, 2027 · next Mar 24
- 2 fees due Apr 8 to 22, 2027 · next Apr 8
- 1 fee due Jul 14, 2027The maintenance fee for Metabotrophic Glutamate Receptor 5 Modulators and Methods of Use Thereof (US 10,533,000) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
- 4 fees due Aug 2 to 25, 2027 · next Aug 2
- 4 fees due Sep 3 to 30, 2027 · next Sep 3
- 1 fee due Nov 3, 2027The maintenance fee for Sublingual Apomorphine (US 9,326,981) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.
Recent changes
- 5 terms have ended since Aug 17, 2026
What they patent
The 5 largest of its 24 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Nonracemic Mixtures and Uses Thereof | 6 in force | to Dec 2038 |
| Crystal Forms and Production Methods Thereof | 4 in force | to Dec 2038 |
| Sublingual Apomorphine | 3 in force | to Jun 2030 |
| Modified Release Formulations and Uses Thereof | 2 in force | to Jun 2040 |
| Salts, Crystal Forms, and Production Methods Thereof | 2 in force | to Feb 2039 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,902,252 | Inhibitors of D-Amino Acid Oxidase In force · High confidence | In force | High confidence | |
| US 8,877,975 | Cycloalkylamines as Monoamine Reuptake Inhibitors Grace period ended · Low confidence | Grace period ended | Low confidence | |
| US 7,718,822 | Carbamate Stereoisomer In force · High confidence | In force | High confidence | |
| US 9,040,588 | Acetamide Stereoisomer In force · High confidence | In force | High confidence | |
| US 8,889,686 | Method of Decreasing the Bitterness of a Pharmaceutical Dosage Form Containing Zopiclone In force · High confidence | In force | High confidence | |
| US 8,053,603 | Tetralone-Based Monoamine Reuptake Inhibitors In force · High confidence | In force | High confidence | |
| US 9,044,475 | Sublingual Apomorphine In force · Medium confidence | In force | Medium confidence | |
| US 9,326,981 | Sublingual Apomorphine In force · High confidence | In force | High confidence | |
| US 10,420,763 | Sublingual Apomorphine In force · Medium confidence | In force | Medium confidence | |
| US 8,957,114 | Formulations, Salts and Polymorphs of Transnorsertraline and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 40: 21 patents in force now held by others · 108 patents ended · 11 applications pending · 89 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.